WuXi AppTec has been granted a patent for an adenoviral vector featuring a regulatable Major Late Promoter (MLP) that includes repressor elements to control transcription of adenoviral late genes. The invention also encompasses cells containing these vectors and related processes. GlobalData’s report on WuXi AppTec gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on WuXi AppTec, AI-assisted drug screening was a key innovation area identified from patents. WuXi AppTec's grant share as of July 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Adenoviral vector with regulatable major late promoter
The granted patent US12071631B2 describes an innovative adenoviral vector designed for gene therapy applications. Central to this invention is a repressible Major Late Promoter (MLP) that regulates the transcription of multiple adenoviral late genes. The MLP includes specific repressor elements, and its nucleotide sequence is defined in the patent. The vector can also incorporate adenoviral early genes and a transgene, which may encode therapeutic polypeptides, virus proteins, or proteins that can form virus-like particles. Notably, the transgene can include a Tripartite Leader (TPL) in its 5'-UTR, enhancing its expression. The patent further specifies potential transgene products, including Norovirus VP1, Hepatitis B HBSAG, and various AAV polypeptides.
Additionally, the patent outlines a process for producing transgene products by infecting mammalian cells with the adenoviral vector, culturing the cells, and isolating the expressed products. The adenoviral vector may also encode a repressor protein that binds to the repressor elements, with transcription controlled by the MLP. Other claims include the potential for the adenoviral vector to encode an adenovirus L4 100K protein, the insertion of transgenes within specific adenoviral regions, and the creation of compositions and kits that facilitate the use of the adenoviral vector. The patent also covers modified mammalian cells containing the adenoviral vector, indicating its utility in various biotechnological and therapeutic contexts.
To know more about GlobalData’s detailed insights on WuXi AppTec, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
